Ignite Creation Date:
2024-05-05 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00470704
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-27
First Post:
2007-05-07
Brief Title:
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer
Sponsor:
Nancy Lin MD
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
06-213
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Nancy Lin MD
Lead Sponsor Class:
OTHER
Responsible Party:
Nancy Lin MD
Responsible Party Title:
Assistant Professor of Medicine
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Dana-Farber Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Novartis | INDUSTRY |
| GlaxoSmithKline | INDUSTRY |